ENTEST GROUP, INC.
ENTEST GROUP, INC. (ETNI): 7 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E -1.00 · 0% dilution
Lead: Preclinical
7 candidates
N/A
N/A
A transparent, data-derived signal for ENTEST GROUP, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10K
Cash
$0
Quarterly Burn
$17K
Runway
—
Revenue
$0
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| ent-576 | Preclinical |
| imenvax i | Preclinical |
| imenvax ii | Preclinical |
| imenvax iii | Preclinical |
| license ip products | Preclinical |
| zan-100 | Preclinical |
| zan-200 | Preclinical |
Frequently asked questions
How many drug candidates are in ENTEST GROUP, INC.'s pipeline?
ENTEST GROUP, INC. (ETNI) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ENTEST GROUP, INC.'s lead drug candidate?
ENTEST GROUP, INC.'s most advanced tracked candidate is ent-576 (Preclinical) for Chronic Obstructive Pulmonary Disease (COPD).
What is ENTEST GROUP, INC.'s market capitalization?
ENTEST GROUP, INC.'s market capitalization is approximately $10K.
Who is the CEO of ENTEST GROUP, INC.?
Mr. Peiwen Yu is the chief executive officer of ENTEST GROUP, INC. (ETNI).
Get the full picture on ENTEST GROUP, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.